Drugs / ONATASERTIB
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05354362 | Mar 2022 → Feb 2023 | relapsed/refractory diffuse large B-cell lymphoma | Antengene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT02031419 | Dec 2013 → Dec 2023 | diffuse large B-cell lymphoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT01896323 | Jul → Aug 2013 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01611467 | Jun → Jul 2012 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01545947 | May 2012 → Dec 2014 | non-small cell lung carcinoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04337463 | Apr 2020 → May 2022 | neoplasm | Sichuan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01177397 | Jul 2010 → Nov 2016 | diffuse large B-cell lymphoma, glioblastoma, hepatocellular carcinoma, hormone receptor-positive breast cancer +3 | Celgene Corporation | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04998760 | Aug 2021 → Jan 2024 | endometrial cancer, ovarian cancer | Qi Zhou | Unknown | No outcome recorded |
| Phase 2 | NCT04518137 | Apr 2021 → May 2022 | cancer | Antengene Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT03591965 | Aug 2018 → Aug 2022 | hepatocellular carcinoma | Antengene Therapeutics Limited | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONATASERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3586404 ↗ |
| Known as | ATG-008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03591965 ↗ |
| Known as | CC-223 | “Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects” NCT03591965 ↗ |
| Action | Inhibit | “mTOR Kinase Inhibitor CC-223” NCT01177397 ↗ |
| Modality | Small molecule | — CHEMBL3586404 ↗ |
| Route | Oral | “CC-223 Administered Orally” NCT01177397 ↗ |
| Target | MTOR | “mTOR Kinase Inhibitor CC-223” NCT01177397 ↗ |